EliteFitness.com Bodybuilding ForumsStanozololsold under many brand names, is an androgen and anabolic steroid AAS medication which was derived from dihydrotestosterone DHT. Unlike most injectable AAS, stanozolol is not esterified and is sold as an aqueous suspension, or in oral tablet form. L-winstrol is one of the AAS commonly used l-winstrol performance-enhancing drugs and is banned from use in sports competition under the auspices of the International Association of Athletics Federations IAAF l-winstrol many other sporting l-winstrol. Additionally, stanozolol has been used in L-winstrol horse racing. Stanozolol has been used in both animals and human patients for a number of conditions.
Stanozolol - Wikipedia
Stanozolol , sold under many brand names, is an androgen and anabolic steroid AAS medication which was derived from dihydrotestosterone DHT. Unlike most injectable AAS, stanozolol is not esterified and is sold as an aqueous suspension, or in oral tablet form. Stanozolol is one of the AAS commonly used as performance-enhancing drugs and is banned from use in sports competition under the auspices of the International Association of Athletics Federations IAAF and many other sporting bodies.
Additionally, stanozolol has been used in US horse racing. Stanozolol has been used in both animals and human patients for a number of conditions. In humans, it has been demonstrated to be successful in treating anaemia and hereditary angioedema , the latter of which it has been specifically approved for the treatment of in some countries. Stanozolol is used for physique- and performance-enhancing purposes by competitive athletes , bodybuilders , and powerlifters.
Side effects of stanozolol include virilization masculinization , hepatotoxicity , and others. Chemical syntheses of stanozolol have been published. Stanozolol is subject to extensive hepatic biotransformation by a variety of enzymatic pathways. Methods for detection in urine specimens usually involve gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry.
Also in , the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval.
The DESI program was intended to classify all pre drugs that were already on the market as effective, ineffective, or needing further study. The drugs were classified as probably effective as adjunctive therapy in the treatment of senile and postmenopausal osteoporosis but only as an adjunct, and in pituitary dwarfism with a specific caveat for dwarfism, "until growth hormone is more available" , and as lacking substantial evidence of effectiveness for several other indications.
In August and September , Sterling submitted more data; the data was not sufficient but the FDA allowed the drug to be continued to be marketed, since there was an unmet need for drugs for osteoporosis and pituitary dwarfism, but Sterling was required to submit more data.
In the FDA removed the dwarfism indication from the label for stanozolol since human growth hormone drugs had come on the market, and mandated that the label for stanozolol and other steroids say: AAS are without value as primary therapy but may be of value as adjunctive therapy. Equal or greater consideration should be given to diet, calcium balance, physiotherapy, and good general health promoting measures.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee considered the data submitted for osteoporosis in two meetings held and the data for aplastic anemia in In April , the FDA announced that the data was not sufficient, and withdrew the marketing authority for stanozolol for senile and postmenopausal osteoporosis and for raising hemoglobin levels in aplastic anemia. Sanofi had stanzolol manufactured in the US by Searle , which stopped making the drug in October In , Lundbeck withdrew stanozolol from the market in the US; as of no other company is marketing stanozolol as a pharmaceutical drug in the US but it can be obtained via a compounding pharmacy.
Pfizer had marketed stanozolol as a veterinary drug; in Pfizer spun off its veterinary business to Zoetis  and in Pfizer transferred the authorizations to market injectable and tablet forms of stanozolol as a veterinary drug to Zoetis. It is used in veterinary medicine as an adjunct in the management of wasting diseases, to stimulate the formation of red blood cells , arouse appetite, and promote weight gain, but the evidence for these uses is weak.
It is used as a performance-enhancing drug in race horses. Its side effects include weight gain, water retention, and difficulty eliminating nitrogen-based waste products and it is toxic to the liver, especially in cats. Because it may promote the growth of tumors, it is contraindicated in dogs with enlarged prostates. Cinryze , Berinert , ecallantide Kalbitor , icatibant Firazyr and Ruconest.
Brand names under which stanozolol is or has been marketed include Anaysynth, Menabol, Neurabol Caps. The tradename Anabol should not be confused with Anabiol. Stanozolol and other synthetic steroids were first banned by the International Olympic Committee and the International Association of Athletics Federations in , after methods to detect them had been developed. Stanozolol is especially widely used by the athletes from post-Soviet countries. From Wikipedia, the free encyclopedia.
Not to be confused with Winstan. The examples and perspective in this article deal primarily with the United States and do not represent a worldwide view of the subject. You may improve this article , discuss the issue on the talk page , or create a new article , as appropriate. January Learn how and when to remove this template message.
The oral form is marketed for human use whereas an aqueous suspension for injection is used in the veterinary field. Hsu 25 April Handbook of Veterinary Pharmacology. Am J Emerg Med. This case is important as stanozolol misuse is relatively common, due to its high oral bioavailability and perceived safety profile compared with other parenteral AAS.
Lowinson and Ruiz's Substance Abuse: Pharmacology Application in Athletic Training. British Journal of Pharmacology. Rodan 19 January Brennan 18 March Testosterone has low oral bioavailability with only about half of an oral dose available after hepatic first-pass metabolism. Some analogues of testosterone e. Journal of Chromatography B. Disposition of Toxic Drugs and Chemicals in Man 8th ed.
Stanozolol, a new anabolic steroid. The Kefauver-Harris Drug Amendments. Food and Drug Administration. FDA aims to remove unapproved drugs from market: Drugs for Human Use: Collins And John R. Retrieved 3 May Veterinary Pharmacology and Therapeutics. Hall 6 December Concise Dictionary of Pharmacological Agents: Pathology, Toxicogenetics, and Criminalistics of Drug Abuse.
Abuse of Androgens and Detection of Illiegal Use. Chapter 24 in Testosterone: Action, Deficiency, Substitution, edited by E. Cambridge University Press, Androstanolone stanolone, dihydrotestosterone, DHT Androstanolone esters Bolazine capronate Drostanolone propionate dromostanolone propionate Epitiostanol Mepitiostane Mesterolone Metenolone acetate methenolone acetate Metenolone enanthate methenolone enanthate Stenbolone acetate Nortestosterone derivatives: Bolandiol dipropionate Nandrolone esters e.
By mouth , intramuscular injection veterinary . Androgen ; Anabolic steroid. AR agonists Testosterone derivatives: